Zhejiang Huakang Pharmaceutical Co., Ltd. (SHA:605077)
China · Delayed Price · Currency is CNY 15.88
-0.26 (-1.61%)
At close: Feb 13, 2026
SHA:605077 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 3,648 | 2,795 | 2,731 | 2,180 | 1,588 | 1,313 |
Other Revenue | 13.79 | 13.79 | 51.27 | 19.52 | 6.47 | 6.66 |
| 3,662 | 2,808 | 2,783 | 2,200 | 1,594 | 1,320 | |
Revenue Growth (YoY) | 28.64% | 0.92% | 26.48% | 38.02% | 20.79% | -12.65% |
Cost of Revenue | 3,019 | 2,198 | 2,111 | 1,696 | 1,227 | 858.18 |
Gross Profit | 642.58 | 610.82 | 671.82 | 503.69 | 367.13 | 461.47 |
Selling, General & Admin | 172.34 | 186.1 | 127.68 | 106.63 | 80.71 | 66.58 |
Research & Development | 138.98 | 128.41 | 124.28 | 99.71 | 84.23 | 65.03 |
Other Operating Expenses | 5.88 | 4.85 | 6.33 | -8.96 | 8.11 | 9.18 |
Operating Expenses | 323.58 | 337.97 | 258.46 | 204.27 | 178.96 | 141.16 |
Operating Income | 319.01 | 272.84 | 413.36 | 299.43 | 188.17 | 320.31 |
Interest Expense | -80.45 | -33.45 | -37.15 | -14.24 | -3.9 | -8.44 |
Interest & Investment Income | 19.98 | 32.12 | 28.27 | 48.53 | 57.7 | 24.23 |
Currency Exchange Gain (Loss) | 15.9 | 15.9 | 7.21 | 26.45 | -2.55 | -6.52 |
Other Non Operating Income (Expenses) | 6.12 | -1.07 | -0.86 | -4.84 | -0.44 | -0.36 |
EBT Excluding Unusual Items | 280.56 | 286.35 | 410.82 | 355.33 | 238.98 | 329.21 |
Gain (Loss) on Sale of Investments | 5.54 | -1.76 | 5.3 | -10.27 | 1.78 | 1.99 |
Gain (Loss) on Sale of Assets | 0.18 | -0.14 | -0.01 | 0.03 | 0.05 | -0.24 |
Asset Writedown | -2.96 | -0.49 | -4.27 | -2.31 | -1.39 | -1.38 |
Other Unusual Items | 2.61 | 2.61 | 10.56 | - | 14.64 | 18.93 |
Pretax Income | 285.93 | 286.57 | 422.4 | 342.78 | 254.07 | 348.52 |
Income Tax Expense | 33.9 | 17.78 | 50.02 | 23.5 | 17.36 | 41.35 |
Earnings From Continuing Operations | 252.03 | 268.79 | 372.38 | 319.28 | 236.71 | 307.17 |
Minority Interest in Earnings | -2.08 | -0.31 | -0.93 | - | - | - |
Net Income | 249.95 | 268.48 | 371.45 | 319.28 | 236.71 | 307.17 |
Net Income to Common | 249.95 | 268.48 | 371.45 | 319.28 | 236.71 | 307.17 |
Net Income Growth | -11.87% | -27.72% | 16.34% | 34.88% | -22.94% | 13.72% |
Shares Outstanding (Basic) | 297 | 298 | 297 | 296 | 288 | 223 |
Shares Outstanding (Diluted) | 323 | 378 | 297 | 296 | 288 | 223 |
Shares Change (YoY) | -8.56% | 27.25% | 0.23% | 3.09% | 28.98% | 0.11% |
EPS (Basic) | 0.84 | 0.90 | 1.25 | 1.08 | 0.82 | 1.38 |
EPS (Diluted) | 0.77 | 0.71 | 1.25 | 1.08 | 0.82 | 1.38 |
EPS Growth | -3.62% | -43.20% | 16.07% | 30.84% | -40.25% | 13.60% |
Free Cash Flow | -227.84 | -1,283 | -71.23 | -267.77 | -96.61 | 82.29 |
Free Cash Flow Per Share | -0.70 | -3.39 | -0.24 | -0.90 | -0.34 | 0.37 |
Dividend Per Share | 0.700 | 0.500 | 0.538 | 0.462 | 0.330 | 0.393 |
Dividend Growth | 29.99% | -7.15% | 16.68% | 40.02% | -16.02% | 66.67% |
Gross Margin | 17.55% | 21.75% | 24.14% | 22.89% | 23.03% | 34.97% |
Operating Margin | 8.71% | 9.71% | 14.85% | 13.61% | 11.80% | 24.27% |
Profit Margin | 6.83% | 9.56% | 13.35% | 14.51% | 14.85% | 23.28% |
Free Cash Flow Margin | -6.22% | -45.69% | -2.56% | -12.17% | -6.06% | 6.24% |
EBITDA | 538.15 | 472.14 | 586.2 | 404.88 | 272.57 | 380.4 |
EBITDA Margin | 14.70% | 16.81% | 21.07% | 18.40% | 17.10% | 28.82% |
D&A For EBITDA | 219.14 | 199.3 | 172.84 | 105.45 | 84.4 | 60.08 |
EBIT | 319.01 | 272.84 | 413.36 | 299.43 | 188.17 | 320.31 |
EBIT Margin | 8.71% | 9.71% | 14.85% | 13.61% | 11.80% | 24.27% |
Effective Tax Rate | 11.86% | 6.20% | 11.84% | 6.86% | 6.83% | 11.87% |
Revenue as Reported | 3,662 | 2,808 | 2,783 | 2,200 | 1,594 | 1,320 |
Advertising Expenses | - | 7.95 | 7.89 | 9.97 | 6.92 | 0.49 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.